Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
01. Oktober 2024 07:45 ET
|
Curium
Curium partners with PeptiDream for clinical development, regulatory filing, and commercialization of prostate cancer therapies in Japan.
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
24. September 2024 08:45 ET
|
Curium
Curium opens new Netherlands facility for Lu-177 production, ensuring a steady supply of this breakthrough cancer therapy isotope for over 100,000 patients
Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España
10. September 2024 04:30 ET
|
Curium US LLC
PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...
Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
10. September 2024 04:30 ET
|
Curium
CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
09. Juli 2024 09:47 ET
|
Curium
Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
17. Juni 2024 08:51 ET
|
Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
17. Juni 2024 08:51 ET
|
Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
05. Juni 2024 05:27 ET
|
Curium
Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
30. Mai 2024 03:00 ET
|
Curium
first doses of PYLCLARI in France for prostate cancer patients
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
30. Mai 2024 03:00 ET
|
Curium US LLC
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...